Zyga Technology enrolled the first four patients in an expanded EVoluSIon Clinical Study. The prospective 40-site, 250-patient trial will evaluate long-term fusion and pain reduction in patients receiving SImmetry® Sacroiliac Joint Fusion.
The company cited figures from Expert Review of Neurotherapeutics, reporting that ~20% of all chronic low back pain derives from the sacroiliac joint.
Initial enrollment of an earlier U.S. 10-site EVoluSIon Study commenced in 1Q15. Zyga was among companies helping to fuel the lively discussion of SI joint treatment at the NASS meeting in 2015, as well.
Zyga Technology enrolled the first four patients in an expanded EVoluSIon Clinical Study. The prospective 40-site, 250-patient trial will evaluate long-term fusion and pain reduction in patients receiving SImmetry® Sacroiliac Joint Fusion.
The company cited figures from Expert Review of Neurotherapeutics, reporting that 0% of all chronic...
Zyga Technology enrolled the first four patients in an expanded EVoluSIon Clinical Study. The prospective 40-site, 250-patient trial will evaluate long-term fusion and pain reduction in patients receiving SImmetry® Sacroiliac Joint Fusion.
The company cited figures from Expert Review of Neurotherapeutics, reporting that ~20% of all chronic low back pain derives from the sacroiliac joint.
Initial enrollment of an earlier U.S. 10-site EVoluSIon Study commenced in 1Q15. Zyga was among companies helping to fuel the lively discussion of SI joint treatment at the NASS meeting in 2015, as well.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
